Abstract
Second-line chemotherapy (CTx) for advanced gastrointestinal neuroendocrine carcinoma (GI-NEC) after platinum-based CTx is adopted according to the guidelines of GI adenocarcinoma or small cell lung cancer in daily practice. Recently, some reports suggested that vascular endothelial growth factor receptor-2 highly expressed in tumor vessels of GI-NEC. In this study, we evaluated the efficacy of ramucirumab (RAM)-containing CTx.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
